+++ Jetzt mit Hebel in Aktien, Indizes, Kryptowährungen, etc. investieren +++ -w-
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
31.10.2019 11:00:00

Acadia Pharmaceuticals Delivers Record Q3 Revenue, Fueled by Antipsychotic Drug Nuplazid

Acadia Pharmaceuticals (NASDAQ: ACAD) has been a huge winner so far in 2019. The biotech's Parkinson's disease psychosis (PDP) medicine Nuplazid (pimavanserin) has picked up significant sales momentum, and it's reported some positive clinical results.The company announced its third-quarter results after the market closed on Wednesday. And Acadia had even more good news. Here are the highlights from the drugmaker's Q3 update.Image source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"